Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial

Table 5

Genotype distribution of rs2228001 in the treatment response categories partial response/stable disease versus progressive disease*.

Clinical end-point	Genotype distribution
	GG	GT	TT	𝑃 value
PR + SD	5 (38.5)	7 (53.8)	1 (7.7)
PD	1 (20.0)	1 (20.0)	3 (60.0)	0.057

* Number in brackets indicate percentages within each clinical level.